Coya Therapeutics (COYA) Competitors

$4.80 -0.05 (-0.93%)

As of 01:58 PM Eastern

COYA vs. RCKT, SNDL, OVID, IRD, and PBYI

Should you buy Coya Therapeutics stock or one of its competitors? MarketBeat compares Coya Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Coya Therapeutics include Rocket Pharmaceuticals (RCKT), SNDL (SNDL), Ovid Therapeutics (OVID), Opus Genetics (IRD), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry.

How does Coya Therapeutics compare to Rocket Pharmaceuticals?

Coya Therapeutics (NASDAQ:COYA) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Coya Therapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

In the previous week, Rocket Pharmaceuticals had 5 more articles in the media than Coya Therapeutics. MarketBeat recorded 6 mentions for Rocket Pharmaceuticals and 1 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.29 beat Rocket Pharmaceuticals' score of -0.25 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rocket Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Coya Therapeutics presently has a consensus target price of $16.00, suggesting a potential upside of 233.68%. Rocket Pharmaceuticals has a consensus target price of $11.54, suggesting a potential upside of 277.69%. Given Rocket Pharmaceuticals' higher probable upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rocket Pharmaceuticals	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 12.0% of Coya Therapeutics shares are held by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Coya Therapeutics has higher revenue and earnings than Rocket Pharmaceuticals. Coya Therapeutics is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.94M	14.17	-$21.23M	-$1.15	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

Rocket Pharmaceuticals has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

Summary

Coya Therapeutics and Rocket Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Coya Therapeutics compare to SNDL?

SNDL (NASDAQ:SNDL) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

In the previous week, Coya Therapeutics had 1 more articles in the media than SNDL. MarketBeat recorded 1 mentions for Coya Therapeutics and 0 mentions for SNDL. Coya Therapeutics' average media sentiment score of 0.29 beat SNDL's score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
SNDL	Neutral
Coya Therapeutics	Neutral

SNDL has higher revenue and earnings than Coya Therapeutics. SNDL is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SNDL	$677.32M	0.55	-$11.29M	-$0.03	N/A
Coya Therapeutics	$7.94M	14.17	-$21.23M	-$1.15	N/A

39.8% of Coya Therapeutics shares are held by institutional investors. 12.0% of Coya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

SNDL presently has a consensus target price of $5.00, suggesting a potential upside of 243.64%. Coya Therapeutics has a consensus target price of $16.00, suggesting a potential upside of 233.68%. Given SNDL's higher possible upside, equities analysts plainly believe SNDL is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SNDL	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

SNDL has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

SNDL has a net margin of -1.19% compared to Coya Therapeutics' net margin of -266.10%. SNDL's return on equity of -1.02% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SNDL	-1.19%	-1.02%	-0.85%
Coya Therapeutics	-266.10%	-55.86%	-48.86%

Summary

SNDL and Coya Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Coya Therapeutics compare to Ovid Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Coya Therapeutics presently has a consensus price target of $16.00, indicating a potential upside of 233.68%. Ovid Therapeutics has a consensus price target of $5.13, indicating a potential upside of 106.24%. Given Coya Therapeutics' higher probable upside, research analysts plainly believe Coya Therapeutics is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 12.0% of Coya Therapeutics shares are owned by company insiders. Comparatively, 13.1% of Ovid Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Ovid Therapeutics has a net margin of -240.11% compared to Coya Therapeutics' net margin of -266.10%. Ovid Therapeutics' return on equity of -22.51% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
Ovid Therapeutics	-240.11%	-22.51%	-18.67%

Coya Therapeutics has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.18, suggesting that its stock price is 82% less volatile than the broader market.

In the previous week, Coya Therapeutics and Coya Therapeutics both had 1 articles in the media. Coya Therapeutics' average media sentiment score of 0.29 beat Ovid Therapeutics' score of -0.83 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ovid Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Ovid Therapeutics has lower revenue, but higher earnings than Coya Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.94M	14.17	-$21.23M	-$1.15	N/A
Ovid Therapeutics	$7.25M	45.20	-$17.41M	-$0.29	N/A

Summary

Ovid Therapeutics beats Coya Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Coya Therapeutics compare to Opus Genetics?

Opus Genetics (NASDAQ:IRD) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

Coya Therapeutics has lower revenue, but higher earnings than Opus Genetics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	24.85	-$49.59M	-$1.33	N/A
Coya Therapeutics	$7.94M	14.17	-$21.23M	-$1.15	N/A

Opus Genetics has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

Opus Genetics presently has a consensus target price of $10.18, indicating a potential upside of 134.87%. Coya Therapeutics has a consensus target price of $16.00, indicating a potential upside of 233.68%. Given Coya Therapeutics' higher possible upside, analysts clearly believe Coya Therapeutics is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.80
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Coya Therapeutics has a net margin of -266.10% compared to Opus Genetics' net margin of -892.36%. Coya Therapeutics' return on equity of -55.86% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-892.36%	-338.88%	-191.21%
Coya Therapeutics	-266.10%	-55.86%	-48.86%

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 11.7% of Opus Genetics shares are held by insiders. Comparatively, 12.0% of Coya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Opus Genetics had 9 more articles in the media than Coya Therapeutics. MarketBeat recorded 10 mentions for Opus Genetics and 1 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.29 beat Opus Genetics' score of 0.17 indicating that Coya Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Coya Therapeutics beats Opus Genetics on 9 of the 17 factors compared between the two stocks.

How does Coya Therapeutics compare to Puma Biotechnology?

Coya Therapeutics (NASDAQ:COYA) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 12.0% of Coya Therapeutics shares are owned by company insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Puma Biotechnology has higher revenue and earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.94M	14.17	-$21.23M	-$1.15	N/A
Puma Biotechnology	$228.40M	1.58	$31.11M	$0.48	14.78

In the previous week, Coya Therapeutics and Coya Therapeutics both had 1 articles in the media. Puma Biotechnology's average media sentiment score of 0.49 beat Coya Therapeutics' score of 0.29 indicating that Puma Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Puma Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Coya Therapeutics has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

Puma Biotechnology has a net margin of 10.69% compared to Coya Therapeutics' net margin of -266.10%. Puma Biotechnology's return on equity of 20.30% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
Puma Biotechnology	10.69%	20.30%	12.05%

Coya Therapeutics presently has a consensus price target of $16.00, indicating a potential upside of 233.68%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Coya Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Puma Biotechnology beats Coya Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Coya Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COYA vs. The Competition

Export

Metric	Coya Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$112.24M	$3.38B	$6.38B	$12.34B
Dividend Yield	N/A	2.30%	2.79%	5.33%
P/E Ratio	-4.16	19.04	20.91	25.65
Price / Sales	14.17	298.20	543.80	85.61
Price / Cash	N/A	129.82	44.13	56.16
Price / Book	2.29	6.98	10.09	7.06
Net Income	-$21.23M	$24.45M	$3.55B	$335.04M
7 Day Performance	-3.33%	3.54%	4.71%	2.60%
1 Month Performance	8.73%	-0.26%	1.43%	1.42%
1 Year Performance	-16.02%	62.90%	36.72%	35.67%

Coya Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COYA Coya Therapeutics	2.6083 of 5 stars	$4.80 -0.9%	$16.00 +233.7%	-14.6%	$112.24M	$7.94M	N/A	6
RCKT Rocket Pharmaceuticals	2.187 of 5 stars	$3.64 +1.4%	$11.54 +217.0%	-53.0%	$392.01M	N/A	N/A	240
SNDL SNDL	2.851 of 5 stars	$1.41 -1.4%	$5.00 +254.6%	+12.2%	$368.08M	$677.32M	N/A	2,751
OVID Ovid Therapeutics	2.2858 of 5 stars	$2.87 +2.9%	$4.63 +61.1%	+754.0%	$367.93M	$7.25M	N/A	60	High Trading Volume
IRD Opus Genetics	3.4293 of 5 stars	$5.18 +1.2%	$10.30 +98.8%	+320.6%	$365.58M	$14.20M	N/A	14	Analyst Forecast Insider Trade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COYA) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coya Therapeutics (COYA) Competitors

COYA vs. RCKT, SNDL, OVID, IRD, and PBYI

How does Coya Therapeutics compare to Rocket Pharmaceuticals?

Summary

How does Coya Therapeutics compare to SNDL?

Summary

How does Coya Therapeutics compare to Ovid Therapeutics?

Summary

How does Coya Therapeutics compare to Opus Genetics?

Summary

How does Coya Therapeutics compare to Puma Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA vs. The Competition

Coya Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coya Therapeutics (COYA) Competitors

COYA vs. RCKT, SNDL, OVID, IRD, and PBYI

How does Coya Therapeutics compare to Rocket Pharmaceuticals?

Which has more risk & volatility, COYA or RCKT?

Does the media prefer COYA or RCKT?

Do analysts prefer COYA or RCKT?

Do institutionals and insiders have more ownership in COYA or RCKT?

Which has preferable valuation & earnings, COYA or RCKT?

Is COYA or RCKT more profitable?

Summary

How does Coya Therapeutics compare to SNDL?

Does the media prefer SNDL or COYA?

Which has higher earnings and valuation, SNDL or COYA?

Do institutionals & insiders hold more shares of SNDL or COYA?

Do analysts rate SNDL or COYA?

Which has more volatility & risk, SNDL or COYA?

Is SNDL or COYA more profitable?

Summary

How does Coya Therapeutics compare to Ovid Therapeutics?

Do analysts rate COYA or OVID?

Do insiders & institutionals believe in COYA or OVID?

Is COYA or OVID more profitable?

Which has more risk and volatility, COYA or OVID?

Does the media favor COYA or OVID?

Which has stronger earnings & valuation, COYA or OVID?

Summary

How does Coya Therapeutics compare to Opus Genetics?

Which has higher earnings & valuation, IRD or COYA?

Which has more volatility & risk, IRD or COYA?

Do analysts prefer IRD or COYA?

Is IRD or COYA more profitable?

Do institutionals and insiders believe in IRD or COYA?

Does the media refer more to IRD or COYA?

Summary

How does Coya Therapeutics compare to Puma Biotechnology?

Do institutionals & insiders hold more shares of COYA or PBYI?

Which has higher earnings & valuation, COYA or PBYI?

Does the media favor COYA or PBYI?

Which has more volatility and risk, COYA or PBYI?

Is COYA or PBYI more profitable?

Do analysts prefer COYA or PBYI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA vs. The Competition

Coya Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools